SCHEMBL14749291

SCHEMBL14749291

Cc1ccc(-c2cc(C3CCC(c4ccccc4)NC3)n(-c3ncccn3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 10/20 0.46
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ STAT1 P42224 1/20 0.38
▸ RAD51 Q06609 1/20 0.33
▸ TP53 P04637 2/20 0.33
▸ GSK3B P49841 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12184580 0.91 PRCP (0.56) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL2598787 0.91 PRCP (0.56) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL12184727 0.90 PRCP (0.54) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL14749308 0.90 PRCP (0.54) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL14749289 0.84 PRCP (0.56) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL14749294 0.74 PRCP (0.47) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL14749284 0.74 PRCP (0.49) PRCPNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL12183895 0.74 PRCP (0.56) PRCP
SCHEMBL14737307 0.74 PRCP (0.56) PRCP
SCHEMBL14701326 0.73 PRCP (0.83) PRCPALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885NPC1 1944/4885RAB9A 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback